Pre-Tax Income: Company's earnings or loss before taxes on income have been accounted for.
CRISPR Therapeutics AG (CRSP) had Pre-Tax Income of $-134.89M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$0.86M |
|
$-136.00M |
|
-- |
|
$0.86M |
|
$149.29M |
|
$-148.42M |
|
$13.54M |
|
|
Pre-Tax Income |
$-134.89M |
$-134.89M |
|
$-136.00M |
|
$-136.00M |
|
$-136.00M |
|
$-136.00M |
|
$-148.42M |
|
$-143.69M |
|
85.94M |
|
85.94M |
|
$-1.58 |
|
$-1.58 |
|
| Balance Sheet Financials | |
$1.87B |
|
$129.43M |
|
$298.49M |
|
$2.17B |
|
$119.45M |
|
-- |
|
$217.50M |
|
$336.94M |
|
$1.83B |
|
$1.83B |
|
$1.83B |
|
86.36M |
|
| Cash Flow Statement Financials | |
$-53.95M |
|
$-19.75M |
|
$10.59M |
|
$309.78M |
|
$246.70M |
|
$-63.07M |
|
$20.21M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.64 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-17158.84% |
|
-17158.84% |
|
-- |
|
-15593.87% |
|
-15722.08% |
|
$-54.15M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-7.43% |
|
-7.43% |
|
-6.28% |
|
-7.43% |
|
$21.18 |
|
$-0.63 |
|
$-0.63 |
|